BACKGROUND: COX inhibitors and beta-blockers were recently suggested to reduce cancer progression through inhibition of tumor proliferation and growth factor secretion, induction of tumor apoptosis, and prevention of cellular immune suppression during the critical perioperative period. Here we evaluated the perioperative impact of clinically applicable drugs from these categories in the context of surgery, studying natural killer (NK) cell activity and resistance to experimental metastases. METHODS: F344 rats were treated with COX-1 inhibitors (SC560), COX-2 inhibitors (indomethacin, etodolac, or celecoxib), a beta-blocker (propranolol), or a combination of a COX-2 inhibitor and a beta-blocker (etodolac and propranolol). Rats underwent laparotomy, and were inoculated intravenously with syngeneic MADB106 tumor cells for the assessment of lung tumor retention (LTR). Additionally, the impact of these drug regimens on postoperative levels of NK cytotoxicity was studied in peripheral blood and marginating-pulmonary leukocytes. RESULTS: Surgery increased MADB106 LTR. COX-2 inhibition, but not COX-1 inhibition, reduced postoperative LTR. Etodolac and propranolol both attenuated the deleterious impact of surgery, and their combined use abolished it. Surgery decreased NK cytotoxicity per NK cell in both immune compartments, and only the combination of etodolac and propranolol significantly attenuated these effects. Lastly, the initiation of drug treatment three days prior to surgery yielded the same beneficial effects as a single pre-operative administration, but, as discussed, prolonged treatment may be more advantageous clinically. CONCLUSIONS: Excess prostaglandin and catecholamine release contributes to postoperative immune-suppression. Treatment combining perioperative COX-2 inhibition and beta-blockade is practical in operated cancer patients, and our study suggests potential immunological and clinical benefits.
BACKGROUND: COX inhibitors and beta-blockers were recently suggested to reduce cancer progression through inhibition of tumor proliferation and growth factor secretion, induction of tumor apoptosis, and prevention of cellular immune suppression during the critical perioperative period. Here we evaluated the perioperative impact of clinically applicable drugs from these categories in the context of surgery, studying natural killer (NK) cell activity and resistance to experimental metastases. METHODS: F344 rats were treated with COX-1 inhibitors (SC560), COX-2 inhibitors (indomethacin, etodolac, or celecoxib), a beta-blocker (propranolol), or a combination of a COX-2 inhibitor and a beta-blocker (etodolac and propranolol). Rats underwent laparotomy, and were inoculated intravenously with syngeneic MADB106 tumor cells for the assessment of lung tumor retention (LTR). Additionally, the impact of these drug regimens on postoperative levels of NK cytotoxicity was studied in peripheral blood and marginating-pulmonary leukocytes. RESULTS: Surgery increased MADB106 LTR. COX-2 inhibition, but not COX-1 inhibition, reduced postoperative LTR. Etodolac and propranolol both attenuated the deleterious impact of surgery, and their combined use abolished it. Surgery decreased NK cytotoxicity per NK cell in both immune compartments, and only the combination of etodolac and propranolol significantly attenuated these effects. Lastly, the initiation of drug treatment three days prior to surgery yielded the same beneficial effects as a single pre-operative administration, but, as discussed, prolonged treatment may be more advantageous clinically. CONCLUSIONS: Excess prostaglandin and catecholamine release contributes to postoperative immune-suppression. Treatment combining perioperative COX-2 inhibition and beta-blockade is practical in operated cancerpatients, and our study suggests potential immunological and clinical benefits.
Authors: Susan K Lutgendorf; Anil K Sood; Barrie Anderson; Stephanie McGinn; Heena Maiseri; Minh Dao; Joel I Sorosky; Koen De Geest; Justine Ritchie; David M Lubaroff Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Anil K Sood; Robert Bhatty; Aparna A Kamat; Charles N Landen; Liz Han; Premal H Thaker; Yang Li; David M Gershenson; Susan Lutgendorf; Steven W Cole Journal: Clin Cancer Res Date: 2006-01-15 Impact factor: 12.531
Authors: Michael A Kern; Anke M Haugg; Andreas F Koch; Tobias Schilling; Kai Breuhahn; Henning Walczak; Binje Fleischer; Christian Trautwein; Christoph Michalski; Henning Schulze-Bergkamen; Helmut Friess; Wolfgang Stremmel; Peter H Krammer; Peter Schirmacher; Martina Müller Journal: Cancer Res Date: 2006-07-15 Impact factor: 12.701
Authors: Lee-Hwa Tai; Christiano Tanese de Souza; Shalini Sahi; Jiqing Zhang; Almohanad A Alkayyal; Abhirami Anu Ananth; Rebecca A C Auer Journal: J Vis Exp Date: 2014-03-12 Impact factor: 1.355
Authors: Jennifer M Knight; J Douglas Rizzo; Brent R Logan; Tao Wang; Jesusa M G Arevalo; Jeffrey Ma; Steve W Cole Journal: Clin Cancer Res Date: 2015-08-18 Impact factor: 12.531